{
    "Rank": 529,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01814150",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "A1AGP1234"
                },
                "Organization": {
                    "OrgFullName": "Meir Medical Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel",
                "OfficialTitle": "The Association Between Alpha 1 Acid Glycoprotein Level and Outcome of Patients With Metastatic Cancer Treated With Docetaxel Based Chemotherapy"
            },
            "StatusModule": {
                "StatusVerifiedDate": "March 2013",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Not yet recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "April 2013"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "April 2016",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "April 2018",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "March 5, 2013",
                "StudyFirstSubmitQCDate": "March 15, 2013",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "March 19, 2013",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "March 22, 2013",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "March 25, 2013",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor-Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Gottfried Maya",
                    "ResponsiblePartyInvestigatorTitle": "Head, Institution of Oncology",
                    "ResponsiblePartyInvestigatorAffiliation": "Meir Medical Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Gottfried Maya",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.\n\nOne of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein.\n\nRetrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients.\n\nThe investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.",
                "DetailedDescription": "Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.\n\nOne of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein\n\nRetrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in non small cell lung cancer patients.\n\nThe investigators aim to prospectively study the association between the baseline plasma level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of docetaxel) and the outcome (response rete, progression free survival, overall survival) of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, stomach cancer, prostate cancer, and bladder cancer."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Metastatic Lung Cancer",
                        "Metastatic Breast Cancer",
                        "Metastatic Gastric Cancer",
                        "Metastatic Prostate Cancer",
                        "Metastatic Bladder Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Docetaxel",
                        "Alpha 1 Acid Glycoprotein",
                        "Outcome"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "PatientRegistry": "No",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Cohort"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "200",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Oncology Institute, Meir Medical Center",
                            "ArmGroupDescription": "Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center"
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic cancer",
                            "PrimaryOutcomeDescription": "The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer",
                            "PrimaryOutcomeTimeFrame": "3 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "The association between the baseline plasma level of alpha 1 acid glycoprotein and the response rate and overall survival of docetaxel based therapy in patients with metastatic cancer",
                            "SecondaryOutcomeDescription": "The association between the baseline plasma level of alpha 1 acid glycoprotein and the response rate and overall survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria\n\npatients with metastatic cancer from lung, breast, gastric, prostate, and bladder origin\npatients must be treated with docetaxel based chemotherapy\npatients must sign an informed consent form\n\nExclusion Criteria\n\npatients with metastatic cancer other than lung, breast, gastric, prostate, and bladder origin\npatients treated with chemotherapy other than docetaxel\npatients that did not sign an informed consent form",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Patients with Metastatic cancer from lung, breast, gastric, prostate, and bladder origin, treated with docetaxel based chemotherapy",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Daniel Keizman, MD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "97297471408",
                            "CentralContactEMail": "danielkeizman@gmail.com"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Daniel Keizman, MD",
                            "OverallOfficialAffiliation": "Meir Medical Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Institute of Oncology, Meir Medical Center",
                            "LocationCity": "Kfar-Saba",
                            "LocationCountry": "Israel",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Daniel Keizman, MD",
                                        "LocationContactRole": "Principal Investigator"
                                    }
                                ]
                            }
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000009362",
                            "ConditionMeshTerm": "Neoplasm Metastasis"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009385",
                            "ConditionAncestorTerm": "Neoplastic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000010335",
                            "ConditionAncestorTerm": "Pathologic Processes"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafAsFound": "Metastatic Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14025",
                            "ConditionBrowseLeafName": "Prostatic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15754",
                            "ConditionBrowseLeafName": "Stomach Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4720",
                            "ConditionBrowseLeafName": "Urinary Bladder Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12020",
                            "ConditionBrowseLeafName": "Neoplastic Processes",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T5486",
                            "ConditionBrowseLeafName": "Stomach Cancer",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1668",
                            "InterventionBrowseLeafName": "Docetaxel",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M340754",
                            "InterventionBrowseLeafName": "polysaccharide-K",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infe",
                            "InterventionBrowseBranchName": "Anti-Infective Agents"
                        }
                    ]
                }
            }
        }
    }
}